UNSPSC 51385607: Magnesium salicylate

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula 2C7H5O3.Mg.4H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 41728CY7UX, chemically known as magnesium, bis(2-(hydroxy-kappao)benzoato-kappao)-, (t-4)- but generally known as magnesium salicylate, which bears US NIH Compound Identifier 64738. European Medicines Agency schedules Magnesium salicylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14444MIG.

As of Q4 2014, MAGNESIUM SALICYLATE remains the US FDA Preferred Term for this commodity. Magnesium salicylate bears US NLM identifiers UMLS ID C0126789 and NCI Concept Code C66050. SMILES: C1=CC=C(C(=C1)C(=O)O)[O-].C1=CC=C(C(=C1)C(=O)O)[O-].[MG+2].

UNSPSC 51385607 Magnesium salicylate is a Commodity code that in recent practice encompasses pharmaceutical products and over-the-counter medications procured through state and local health agencies, cooperative purchasing alliances, and county health departments for distribution to public facilities and community health programs. State and local governments are buying generic pharmaceuticals, OTC products, and emergency medical supplies (including naloxone and drug deactivation systems) under this code, typically through competitive bidding processes that require vendors to maintain FDA compliance, Good Manufacturing Practices certification, and established relationships with authorized pharmaceutical wholesalers. Issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances that aggregate demand across multiple jurisdictions and member facilities.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS (due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 (April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, seeking information on direct contracting capacity outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 (due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers to participating state and local facilities in Minnesota and Oregon, with awarded vendors effective July 1, 2026 and contract pricing weighted 75 percent on competitiveness. All three solicitations require compliance with Drug Supply Chain Security Act, FDA regulations, and established insurance and worker verification standards.